Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 6, 2001, Pages 971-976

  Wilson, Duncan R ^a   Nouri Aria, Kayhan T ^a   Walker, Samantha M ^a   Pajno, Giovanni B ^a   O'Brien, Fiona ^a   Jacobson, Mikila R ^a   Mackay, Ian S ^a   Durham, Stephen R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Allergic rhinitis; Eosinophils; IL 5; Immunotherapy

Indexed keywords

INTERLEUKIN 5;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; EFFECTOR CELL; EOSINOPHILIA; FEMALE; GRASS POLLEN; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; MALE; MESSENGER RNA SYNTHESIS; NOSE MUCOSA; POLLEN ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

EID: 0035016912     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.115483     Document Type: Article

References (41)

1. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cells
2. Interleukin-5 and the regulation of eosinophil production
3. Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: Relationship to tissue eosinophilia
4. Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids
5. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis
6. Two types of murine helper T cell clone. I definition according to profiles of lymphokine activities and secreted proteins
7. The Th1/Th2 paradigm in allergic disorders
8. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs
9. World Health Organization position paper. Allergen immunotherapy: Therapeutic vaccines for allergic diseases
10. Long-term clinical efficacy of grass-pollen immunotherapy
11. IgG subclass antibody response in grass pollen allergic patients undergoing specific immunotherapy. Prognostic value of serum IgG subclass antibody levels early in immunotherapy
12. Grass pollen immunotherapy decreases the number of mast cells in the skin
13. Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity
14. Role of interleukin 10 in specific immunotherapy
15. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized controlled trial
16. A biopsy method to obtain high quality specimens of nasal mucosa
17. Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T Iymphocytes, eosinophils, and neutrophils
18. Cytotoxicity of human eosinophil granule major basic protein to human nasal sinus mucosa in vitro
19. Identification of messenger RNA for IL-4 in human eosinophils with granule localisation and release of the translated product
20. Eosinophils express interleukin-5 and granulocyte macrophage colony stimulating factor mRNA at sites of allergic inflammation in asthmatics
21. IL-5 production by NK cells contributes to eosinophil infiltration in a mouse model of allergic inflammation
22. Eosinophil development and bone marrow and tissue eosinophils in atopic asthma
23. The phenotype of human eosinophils, basophils and mast cells
24. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo
25. IL-5 dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity
26. Recombinant human interleukin 5 is a selective activator of human eosinophil function
27. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CDI 1/18)-dependent manner
28. IL-5 as a strong secretagogue for human eosinophils
29. Analysis of the prolongation of rat eosinophil survival induced by recombinant rat interleukin-5
30. Recombinant human interleukin 5 is a selective eosinophil chemoattractant
31. The effect of recombinant human interleukin-5 on eosinophil accumulation and degranulation in human nasal mucosa
32. Development of lung eosinophilic inflammation by the infusion of IL-5-producing T cell clones
33. Interleukin-5 deficiency abolishes eosinophilia, airways hyperreactivity and lung damage in a mouse asthma model
34. Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6 and IgE antibody production are unaffected
35. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma
36. CD34(+)/interleukin-5Ralpha messenger RNA+ cells in the bronchial mucosa in asthma: Potential airway eosinophil progenitors
37. Evidence for local eosinophiI differentiation within allergic nasal mucosa: Inhibition with soluble IL-5 receptor
38. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice
39. Grass pollen immunotherapy: Efficacy and safety during a 4-year follow-up study
40. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma
41. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsivenesss and the late asthmatic response